KOSDAQBiotech & Pharma461030

IMBdx

₩2,025▼ 2.17%2026-11-18 close
Market Cap
₩29B
Turnover
₩51,760,350
Volume
30K
Shares out.
14.3M
PER
—
PBR
1.4×
EPS
-₩558
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Losses in Five Consecutive Quarters Despite Sales Growth

IMBdx grew 2025 sales to KRW 5.33 billion, up 56.4% year on year, yet its operating loss of KRW 8.66 billion extended a three-year run of losses, leaving the durability of loss reduction as the key item for the next annual report.

  1. 1

    Sales reached KRW 5.33 billion in 2025, the largest year in 2023–2025, and the company attributed the increase to a product upgrade launch and wider market recognition.

  2. 2

    The operating loss narrowed to KRW 8.66 billion in 2025 from KRW 10.6 billion in 2024, and the operating margin improved from -311.5% to -162.6%.

  3. 3

    Third-quarter 2026 sales were KRW 1.21 billion, up 8.1% year on year, while the net loss attributable to controlling shareholders widened to KRW 2.62 billion.

  4. 4

    The net loss attributable to controlling shareholders totaled KRW 7.9 billion over the last four quarters, against equity of KRW 25.2 billion at the end of 2025 and total liabilities of KRW 1.96 billion.

  5. 5

    Press reports cited a 2026 sales target of KRW 10 billion, while sales for the first three quarters of 2026 add up to about KRW 3.99 billion.

02

Business structure

IMBdx is a next-generation sequencing based liquid biopsy company founded in 2018, offering products that cover early cancer detection, advanced cancer analysis and post-surgery recurrence monitoring through circulating tumor DNA.

Its core Alpha Liquid product line accounted for 80% of sales in the first quarter of 2025, followed by CancerDetect at 6%, CancerFind at 4%, and services and other items at 10%, according to a securities firm review.

The same review described Alpha Liquid 100 as the only product listed for National Health Insurance coverage, which means insurance status directly affects domestic prescription volume.

A Korean IR advisory research note put the 2024 mix at 72% for Alpha Liquid, 14% for CancerFind and 4% for CancerDetect, but the two sets of figures cover different periods and cannot be read as one trend.

CancerFind, the multi-cancer early screening test, expanded its detectable cancer types to 12, according to a company IR news item dated December 5, 2025.

Customers include major hospitals such as Seoul National University Hospital and Samsung Medical Center as well as health screening centers, and the product was supplied to 37 major hospitals as of the first quarter of 2025.

Overseas, the company has widened its channels through a supply deal with Inocrass in the United States, a companion diagnostic supply with Bold Therapeutics in Canada, and a Japanese branch with a contract with MedPeer Group. In Taiwan, the company said in 2024 that its profiling product ranked second by market share.

In competition, IMBdx emphasizes its full cancer-lifecycle product mix as a differentiator and competes for hospital channels against domestic and overseas diagnostic companies.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩1.1B-₩2.6B−230.2%
2025Q4₩1.7B-₩2.2B−128.0%
2026Q1₩1.3B-₩2.5B−192.9%
2026Q2₩1.5B-₩1.4B−93.2%
2026Q3₩1.2B-₩2.1B−172.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2023₩4B-₩7.8B-₩10.4B−192.9%−125.2%18.0%
2024₩3.4B-₩10.6B-₩9.6B−311.5%−29.5%4.9%
2025₩5.3B-₩8.7B-₩7.9B−162.6%−31.5%7.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

On an annual basis, sales were KRW 4.03 billion in 2023, KRW 3.41 billion in 2024 (down 15.4% year on year) and KRW 5.33 billion in 2025 (up 56.4%), making 2025 the largest year and 2024 the smallest within 2023–2025.

The operating loss was KRW 7.77 billion in 2023 and widened to KRW 10.6 billion in 2024 before narrowing to KRW 8.66 billion in 2025, with operating margins of -192.9%, -311.5% and -162.6% respectively.

The net loss attributable to controlling shareholders shrank each year, from KRW 10.4 billion in 2023 to KRW 9.58 billion in 2024 and KRW 7.93 billion in 2025, and the consolidated net loss including non-controlling interests followed the same path.

Operating cash outflows were KRW -6.23 billion in 2023, KRW -6.65 billion in 2024 and KRW -6.2 billion in 2025, so roughly KRW 6 billion a year left the business through operations.

The debt ratio stayed low at 18.0%, 4.9% and 7.8% over the same years, which places the financial burden in the size of operating losses rather than in borrowings.

Quarterly sales rose from KRW 1.12 billion in the third quarter of 2025 to KRW 1.7 billion in the fourth quarter, up 52.5% sequentially, then fell to KRW 1.27 billion in the first quarter of 2026, down 25.1%.

Sales recovered to KRW 1.51 billion in the second quarter of 2026, up 18.4% sequentially, and reached KRW 1.21 billion in the third quarter, down 20.1% sequentially but up 8.1% year on year.

The operating loss narrowed from KRW 2.46 billion in the first quarter of 2026 to KRW 1.41 billion in the second quarter, then widened again to KRW 2.08 billion in the third quarter.

In the third quarter, the operating loss was smaller than the KRW 2.57 billion of a year earlier, but the net loss attributable to controlling shareholders rose to KRW 2.62 billion from KRW 2.31 billion, so non-operating items need to be read alongside operating results.

The net loss attributable to controlling shareholders totaled KRW 7.9 billion over the last four quarters, and whether the product upgrades and wider recognition cited for 2025 growth held up in quarterly sales remains an open question.

A Korean IR advisory research note had estimated 2025 sales at KRW 6.4 billion and an operating loss of KRW 7.7 billion, while the disclosed figures were KRW 5.33 billion and KRW 8.66 billion.

05

Industry analysis

The liquid biopsy market that IMBdx operates in is growing as blood-based tests supplement or replace tissue biopsies. A press report put the rate at which liquid biopsies replace tissue tests at about 7% as of 2025 and expected the shift to accelerate as the technology advances.

The same report cited an annual growth rate of 11.5% for the liquid biopsy market, twice the growth rate of the cancer diagnostics market.

Demand comes from health screening centers, precision medicine tests at large hospitals and companion diagnostics for drug developers, and in 2024 the company said it was pursuing a companion diagnostic collaboration with AstraZeneca for a prostate cancer targeted therapy.

In competition, liquid biopsy companies divide the market among early detection, monitoring during treatment and recurrence surveillance, and IMBdx positions its coverage of all three areas as a differentiator.

Overseas expansion, as reported in 2024, targeted Europe, Japan, Southeast Asia and the Middle East, and the company said its profiling product ranked second by share in Taiwan.

In terms of cycle position, the market appears to be in an early expansion phase, yet a 56.4% sales increase in 2025 alongside an operating margin of -162.6% shows the gap between revenue growth and cost structure improvement.

Compared with large-cap biopharma companies, the company's sales base is small, so changes in the industry may show up in its reported results more strongly.

06

Outlook

The company has presented a 2026 sales target of KRW 10 billion, and press reports said it expects growth of more than 50% over 2025. That target was reported around the end of 2025.

Quarterly sales in 2026 were KRW 1.27 billion in the first quarter, KRW 1.51 billion in the second and KRW 1.21 billion in the third, staying between KRW 1.2 billion and KRW 1.5 billion, and the first three quarters add up to about KRW 3.99 billion.

Reaching the target would therefore require a sharp increase in fourth-quarter sales. The company has said it aims for domestic sales to grow about 80% per year on average by combining upgrades to existing products with new launches.

Press coverage said CancerFind has settled into the health screening market and is expected to generate full-scale sales in 2026. The company has also said a quarterly operating profit could be possible in 2026, but operating losses continued in every quarter of 2026 through the third.

In Japan, the MedPeer Group contract and the Japanese branch are presented as routes to higher sales, so the share of overseas revenue should be tracked alongside them.

The next confirmed filing is the 2026 annual report, and the key checks are how close annual sales came to the KRW 10 billion target and how far the operating loss narrowed from KRW 8.66 billion in 2025.

The product mix in that report will also show whether CancerFind and CancerDetect grew as a share of sales, which would indicate real progress in expansion.

07

Valuation

PER
—
PBR
1.4×
ROE
-33.2%
EPS
-₩558
BPS
₩1,475
Dividend per share
₩0

Because the net loss attributable to controlling shareholders has continued over the last four quarters, the price-to-earnings ratio cannot be calculated, and earnings-based multiples offer little basis for comparison. The price-to-book ratio is above 1 times, which means the shares trade at a premium to net assets.

Equity of KRW 25.2 billion at the end of 2025 was entirely attributable to controlling shareholders, and total liabilities of KRW 1.96 billion are small, so financial leverage is limited. No dividend is paid, so the dividend yield is below the industry average and shareholders receive no cash return from dividends.

Measured against sales, the company's revenue base is small relative to its market capitalization, so how much growth expectations are already priced in is the central point of comparison. Past trading-range multiples are hard to use as a reference because the share price has moved widely since listing.

When compared with listed biopharma peers, the position is gauged through business metrics such as the price-to-book ratio and sales growth rather than earnings multiples.

In the end, the basis for valuation depends on the pace of loss reduction and the durability of sales growth, and the current multiples rest on those assumptions.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Expanding sales base

Sales reached KRW 5.33 billion in 2025, up 56.4% year on year, and the company cited a product upgrade launch and wider recognition as the drivers. CancerFind now covers 12 detectable cancer types, and the MedPeer Group contract in Japan has added an overseas channel.

Quarterly sales in 2026 have stayed between KRW 1.2 billion and KRW 1.5 billion, so the growth trend has not fully reversed.

Narrowing operating loss

The operating loss narrowed from KRW 10.6 billion in 2024 to KRW 8.66 billion in 2025, and the operating margin improved from -311.5% to -162.6%. Quarterly operating losses fell from KRW 2.46 billion in the first quarter of 2026 to KRW 1.41 billion in the second. The company has not yet moved to profit, but these figures point to a recovery in earnings.

Room for liquid biopsy growth

A press report cited an annual growth rate of 11.5% for the liquid biopsy market, twice that of the cancer diagnostics market. The rate at which liquid biopsies replace tissue tests was estimated at about 7% in 2025, which suggests the shift is still early.

The company highlights its products covering early detection, advanced cancer and recurrence monitoring as a strength.

09

Bear factors

Five consecutive loss-making quarters

Losses have continued for five consecutive quarters from the third quarter of 2025 through the third quarter of 2026, and the net loss attributable to controlling shareholders widened to KRW 2.62 billion in the third quarter of 2026. Over the last four quarters, that net loss totaled KRW 7.9 billion.

The operating loss narrowed in the second quarter but widened again to KRW 2.08 billion in the third, so the improvement has not been steady.

Gap to the sales target

The KRW 10 billion sales target reported for 2026 compares with about KRW 3.99 billion across the first three quarters. Third-quarter 2026 sales fell 20.1% sequentially to KRW 1.21 billion. Sales also declined 15.4% in 2024, so quarterly revenue has been volatile.

Continued operating cash outflow

Operating cash flow was KRW -6.23 billion in 2023, KRW -6.65 billion in 2024 and KRW -6.2 billion in 2025, a sustained annual outflow of about KRW 6 billion. Equity of KRW 25.2 billion remained at the end of 2025, but continued losses would reduce that cushion over time. Whether additional funding is needed will depend on the trajectory of cash flow.

10

Risk factors

Earnings and profitability

Operating losses have run for three consecutive years from 2023 through 2025, with a 2025 operating margin of -162.6%. Quarterly operating losses continued through the first three quarters of 2026, so the timing of a move to profit is not yet visible.

If selling, general and administrative and R&D costs do not fall as sales grow, the pace of improvement could remain limited.

Sales target and volatility

A large gap remains between the company's 2026 sales target of KRW 10 billion and first-three-quarter results. Quarterly sales have stayed between KRW 1.2 billion and KRW 1.5 billion in 2026. If the upgrades and new launches do not translate into quarterly sales, the target becomes harder to reach.

Reimbursement and competition

Alpha Liquid 100 is described as the only product listed for National Health Insurance coverage in Korea, so coverage scope and patient cost conditions affect prescription volumes.

The liquid biopsy market includes many domestic and overseas diagnostics companies, which could intensify competition over price and test scope. If the rate at which liquid biopsies replace tissue tests rises more slowly than expected, market expansion could also slow.

11

What to watch next

  1. December 31, 2026 (fiscal year-end)

    This marks the close of the period against which the reported KRW 10 billion sales target will be measured. Sales for the first three quarters of 2026 total about KRW 3.99 billion.

  2. End of March 2027 (annual report filing deadline)

    The 2026 annual report will show full-year sales, operating loss and operating cash flow against the 2025 figures of KRW 5.33 billion, KRW 8.66 billion and KRW -6.2 billion. Its product breakdown will also show whether CancerFind and CancerDetect gained share.

  3. Early 2027 (release timing not yet set)

    If the company releases preliminary fourth-quarter 2026 results, they should be read as provisional figures. Confirmed results will be verified in the periodic report.

12

Overall view

IMBdx's 2025 sales reached KRW 5.33 billion, up 56.4% year on year, and its operating loss narrowed to KRW 8.66 billion from the prior year. The operating margin improved from -311.5% to -162.6%, which points to a recovery in earnings from a loss-making base.

On the other hand, operating losses have continued for three years and losses attributable to controlling shareholders have run for five consecutive quarters, and in the third quarter of 2026 the operating loss narrowed year on year while the net loss attributable to controlling shareholders widened.

The gap between the reported KRW 10 billion sales target for 2026 and roughly KRW 3.99 billion in first-three-quarter sales is also wide.

Strengths include CancerFind's expanded cancer coverage, the Japan contract and the growth potential of the liquid biopsy market, while operating cash outflows, reimbursement conditions and competition remain weaknesses and risks.

With no earnings-based multiple available, valuation is compared through business metrics and the price-to-book ratio. The next checkpoint is the annual sales and operating loss in the 2026 annual report, which will indicate whether the improvement can be sustained.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. m.news.nate.com
  2. imbdx.com
  3. comp.fnguide.com
  4. m.irgo.co.kr
  5. securities.miraeasset.com
  6. pharm.edaily.co.kr
  7. news.bizwatch.co.kr
  8. zdnet.co.kr
  9. medicopharma.co.kr
  10. view.asiae.co.kr
  11. kr.investing.com
  12. investing.com
  13. investing.com
  14. biospace.com
  15. biopharmawatch.com
  16. kr.investing.com
  17. judal.co.kr
  18. simplywall.st

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis